Current
2.4×
5-Year Average
2.7×
All-Time High
7.0×
All-Time Low
1.8×
P/S Ratio daily chart for Bristol-Myers Squibb (BMY)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
Historical P/S Ratio for Bristol-Myers Squibb (BMY) from 2001 to 2025
| 2025 | $110.09B | $48.19B | 2.3× | -0.1× | |
| 2024 | $114.76B | $48.30B | 2.4× | +0.1× | |
| 2023 | $104.01B | $45.01B | 2.3× | -1.0× | |
| 2022 | $151.67B | $46.16B | 3.3× | +0.4× | |
| 2021 | $134.24B | $46.38B | 2.9× | -0.4× | |
| 2020 | $139.69B | $42.52B | 3.3× | -1.4× | |
| 2019 | $122.90B | $26.14B | 4.7× | +0.9× | |
| 2018 | $84.83B | $22.56B | 3.8× | -1.1× | |
| 2017 | $100.25B | $20.78B | 4.8× | -0.2× | |
| 2016 | $97.71B | $19.43B | 5.0× | -1.8× | |
| 2015 | $113.44B | $16.56B | 6.9× | +0.7× | |
| 2014 | $97.99B | $15.88B | 6.2× | +0.8× | |
| 2013 | $87.59B | $16.39B | 5.3× | +2.3× | |
| 2012 | $53.58B | $17.62B | 3.0× | +0.2× | |
| 2011 | $59.59B | $21.24B | 2.8× | +0.5× | |
| 2010 | $45.20B | $19.48B | 2.3× | -0.3× | |
| 2009 | $49.46B | $18.81B | 2.6× | +0.4× | |
| 2008 | $46.03B | $20.89B | 2.2× | -0.5× | |
| 2007 | $52.40B | $19.35B | 2.7× | -0.2× | |
| 2006 | $51.67B | $17.91B | 2.9× | +0.5× | |
| 2005 | $44.93B | $19.21B | 2.3× | -0.2× | |
| 2004 | $49.83B | $19.38B | 2.6× | -0.1× | |
| 2003 | $55.48B | $20.89B | 2.7× | -0.2× | |
| 2002 | $50.49B | $17.47B | 2.9× | -2.2× | |
| 2001 | $98.79B | $19.42B | 5.1× | — |
- 20252.3×
- 20242.4×
- 20232.3×
- 20223.3×
- 20212.9×
- 20203.3×
- 20194.7×
- 20183.8×
- 20174.8×
- 20165.0×
- 20156.9×
- 20146.2×
- 20135.3×
- 20123.0×
- 20112.8×
- 20102.3×
- 20092.6×
- 20082.2×
- 20072.7×
- 20062.9×
- 20052.3×
- 20042.6×
- 20032.7×
- 20022.9×
- 20015.1×
About P/S Ratio at Bristol-Myers Squibb (BMY)
Bristol-Myers Squibb (BMY) P/S ratio is 2.4× as of June 5, 2026. The 5-year average is 2.7×. The sector median currently stands at 3.5×. The current ratio is at the 40th percentile of its own 10-year history.
Bristol-Myers Squibb (BMY) historical P/S ratio has ranged from a low of 1.8× (2024) to a high of 7.0× (2016) in the available daily series.
The price-to-sales (P/S) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) revenue. It is calculated as market cap ÷ TTM revenue (equivalent to share price ÷ TTM revenue per share). Because the denominator (revenue) cannot be negative, P/S is widely used to value unprofitable or pre-profit companies and to make cross-sector comparisons.
Bristol-Myers Squibb P/S Ratio by Year
Bristol-Myers Squibb P/S Ratio 2025: 2.3×
Bristol-Myers Squibb (BMY) P/S ratio in 2025 was 2.3×, contracted from 2.4× the prior year.
Bristol-Myers Squibb P/S Ratio 2024: 2.4×
Bristol-Myers Squibb (BMY) P/S ratio in 2024 was 2.4×, expanded from 2.3× the prior year.
Bristol-Myers Squibb P/S Ratio 2023: 2.3×
Bristol-Myers Squibb (BMY) P/S ratio in 2023 was 2.3×, contracted from 3.3× the prior year.
Bristol-Myers Squibb P/S Ratio 2022: 3.3×
Bristol-Myers Squibb (BMY) P/S ratio in 2022 was 3.3×, expanded from 2.9× the prior year.
Bristol-Myers Squibb P/S Ratio 2021: 2.9×
Bristol-Myers Squibb (BMY) P/S ratio in 2021 was 2.9×.
Sector peers by P/S Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/S Ratio — table
Healthcare peers of Bristol-Myers Squibb (BMY), ranked by P/S ratio.
| 2.1× | |
| 2.1× | |
| 2.1× | |
| 1.9× | |
| 1.9× | |
| 1.7× | |
| 1.6× | |
| 1.6× | |
| 1.4× | |
| 1.4× | |
| 1.1× | |
| 0.8× | |
| 0.7× | |
| 0.6× | |
| 0.6× | |
| 0.5× | |
| 0.3× | |
| 0.3× | |
| 0.3× | |
| 0.2× | |
| 0.2× | |
| 0.2× | |
| 0.2× | |
| 0.2× | |
| 0.1× |
- 2.1×
- 1.7×
- 1.4×
- 1.1×
- 0.7×
- 0.3×
- 0.3×
- 0.2×
- 0.2×
- 0.2×
- 0.1×
Frequently asked questions
Bristol-Myers Squibb (BMY) Key Financials
Charts, filings, and peer comparison for every metric